Indivior profits fall on higher costs ahead of US listing

Pharmaceutical company Indivior reported a fall in interim profits due to rising costs.

The firm on Thursday said pre-tax profit fell to $106m from $119m a year earlier.

However, revenue for the period increased to $428m from $381m year on year and the company held net revenue and adjusted operating income guidance for the full year.

It also increased full year guidance for its sublocade drug to $420m from $390m.

Indivior guided for pre-tax costs of $10m - $15m as it prepared for an additional US listing, with around 50% expected to be recorded as a one-off.

Reporting by Frank Prenesti at Sharecast.com